Increased Circulating Levels of Vitamin D Binding Protein in MS Patients

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2015 Jan 16

PMID 25590278

Citations 18

Authors

Arturo Ottavio Rinaldi

Isabella Sanseverino

Cristina Purificato

Antonio Cortese

Rosella Mechelli

Silvia Francisci

Marco Salvetti

Enrico Millefiorini

Sandra Gessani

Maria Cristina Gauzzi

Affiliations

Soon will be listed here.

Abstract

Vitamin D (vitD) low status is currently considered a main environmental factor in multiple sclerosis (MS) etiology and pathogenesis. VitD and its metabolites are highly hydrophobic and circulate mostly bound to the vitamin D binding protein (DBP) and with lower affinity to albumin, while less than 1% are in a free form. The aim of this study was to investigate whether the circulating levels of either of the two vitD plasma carriers and/or their relationship are altered in MS. We measured DBP and albumin plasma levels in 28 MS patients and 24 healthy controls. MS patients were found to have higher DBP levels than healthy subjects. Concomitant interferon beta therapy did not influence DBP concentration, and the difference with the control group was significant in both females and males. No significant correlation between DBP and albumin levels was observed either in healthy controls or in patients. These observations suggest the involvement of DBP in the patho-physiology of MS.

Citing Articles

Proteomic analysis reveals candidate molecules to mediate cortical pathology and identify possible biomarkers in an animal model of multiple sclerosis.

Silva B, Leal M, Farias M, Nava A, Galvan D, Fernandez E Front Immunol. 2025; 16:1505459.

PMID: 40018028 PMC: 11864942. DOI: 10.3389/fimmu.2025.1505459.

Potential pathogenic and protective genotypes and phenotypes of vitamin D binding protein in multiple sclerosis.

Al-Shammri S, Chattopadhyay A, Mustafa A Front Neurol. 2025; 16:1455779.

PMID: 39990260 PMC: 11842254. DOI: 10.3389/fneur.2025.1455779.

Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes.

Kodosaki E, Watkins W, Loveless S, Kreft K, Richards A, Anderson V J Neuroinflammation. 2024; 21(1):52.

PMID: 38368354 PMC: 10874571. DOI: 10.1186/s12974-024-03036-4.

Association of Blood Levels of Vitamin D and Its Binding Protein with Clinical Phenotypes of Multiple Sclerosis.

Al-Shammri S, Chattopadhyay A, Hanah M, Doi S, Akanji A Biomedicines. 2023; 11(7).

PMID: 37509448 PMC: 10376961. DOI: 10.3390/biomedicines11071808.

Free vitamin D index and vitamin D-binding protein in multiple sclerosis: A presymptomatic case-control study.

Grut V, Bistrom M, Salzer J, Stridh P, Lindam A, Alonso-Magdalena L Eur J Neurol. 2022; 29(8):2335-2342.

PMID: 35582958 PMC: 9545920. DOI: 10.1111/ene.15407.

References

Smolders J, Moen S, Damoiseaux J, Huitinga I, Holmoy T . Vitamin D in the healthy and inflamed central nervous system: access and function. J Neurol Sci. 2011; 311(1-2):37-43. DOI: 10.1016/j.jns.2011.07.033. View

Polman C, Reingold S, Banwell B, Clanet M, Cohen J, Filippi M . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2):292-302. PMC: 3084507. DOI: 10.1002/ana.22366. View

Simon K, Munger K, Ascherio A . Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics. Curr Opin Neurol. 2012; 25(3):246-51. PMC: 4815910. DOI: 10.1097/WCO.0b013e3283533a7e. View

Loken-Amsrud K, Holmoy T, Bakke S, Beiske A, Bjerve K, Bjornara B . Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment. Neurology. 2012; 79(3):267-73. DOI: 10.1212/WNL.0b013e31825fdf01. View

Runia T, Hop W, de Rijke Y, Buljevac D, Hintzen R . Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology. 2012; 79(3):261-6. DOI: 10.1212/WNL.0b013e31825fdec7. View

Stewart N, Simpson Jr S, van der Mei I, Ponsonby A, Blizzard L, Dwyer T . Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology. 2012; 79(3):254-60. DOI: 10.1212/WNL.0b013e31825fded9. View

Jeffery L, Wood A, Qureshi O, Hou T, Gardner D, Briggs Z . Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. J Immunol. 2012; 189(11):5155-64. PMC: 3504609. DOI: 10.4049/jimmunol.1200786. View

Yang M, Qin Z, Zhu Y, Li Y, Qin Y, Jing Y . Vitamin D-binding protein in cerebrospinal fluid is associated with multiple sclerosis progression. Mol Neurobiol. 2013; 47(3):946-56. DOI: 10.1007/s12035-012-8387-1. View

James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan S . The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler. 2013; 19(12):1571-9. DOI: 10.1177/1352458513489756. View

10.

Powe C, Evans M, Wenger J, Zonderman A, Berg A, Nalls M . Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013; 369(21):1991-2000. PMC: 4030388. DOI: 10.1056/NEJMoa1306357. View

11.

Ascherio A, Munger K, White R, Kochert K, Simon K, Polman C . Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014; 71(3):306-14. PMC: 4000029. DOI: 10.1001/jamaneurol.2013.5993. View

12.

Smolders J, Peelen E, Thewissen M, Menheere P, Damoiseaux J, Hupperts R . Circulating vitamin D binding protein levels are not associated with relapses or with vitamin D status in multiple sclerosis. Mult Scler. 2013; 20(4):433-7. DOI: 10.1177/1352458513500552. View

13.

Carter G, Phinney K . Assessing vitamin D status: time for a rethink?. Clin Chem. 2014; 60(6):809-11. DOI: 10.1373/clinchem.2013.219386. View

14.

Harvey N, Holroyd C, Ntani G, Javaid K, Cooper P, Moon R . Vitamin D supplementation in pregnancy: a systematic review. Health Technol Assess. 2014; 18(45):1-190. PMC: 4124722. DOI: 10.3310/hta18450. View

15.

Chun R, Peercy B, Orwoll E, Nielson C, Adams J, Hewison M . Vitamin D and DBP: the free hormone hypothesis revisited. J Steroid Biochem Mol Biol. 2013; 144 Pt A:132-7. PMC: 3976473. DOI: 10.1016/j.jsbmb.2013.09.012. View

16.

Kongsbak M, von Essen M, Levring T, Schjerling P, Woetmann A, Odum N . Vitamin D-binding protein controls T cell responses to vitamin D. BMC Immunol. 2014; 15:35. PMC: 4177161. DOI: 10.1186/s12865-014-0035-2. View

17.

Willnow T, Nykjaer A . Pathways for kidney-specific uptake of the steroid hormone 25-hydroxyvitamin D3. Curr Opin Lipidol. 2002; 13(3):255-60. DOI: 10.1097/00041433-200206000-00004. View

18.

AARSKOG D, Aksnes L, Markestad T, Rodland O . Effect of estrogen on vitamin D metabolism in tall girls. J Clin Endocrinol Metab. 1983; 57(6):1155-8. DOI: 10.1210/jcem-57-6-1155. View

19.

Bikle D, Siiteri P, Ryzen E, Haddad J . Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J Clin Endocrinol Metab. 1985; 61(5):969-75. DOI: 10.1210/jcem-61-5-969. View

20.

Mendel C . The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev. 1989; 10(3):232-74. DOI: 10.1210/edrv-10-3-232. View